Biotech · Public company · Warminster, PA, US

Arbutus Biopharma Corp

Ticker ABUS · SEC CIK 0001447028

Track this companyFree. Adds Arbutus Biopharma Corp to your Dealase workspace and tells you when its record changes.

Clinical trials52 recruiting or active

Pipeline programs5From trials and the company's site

Disclosed deals0None found yet

Cash runwayNot availableNo recent cash burn filed

Pipeline5

Intrahepatic and Peripheral Responses to Imdusiran (AB-729) in Chronic Hepatitis BPHASE2 · RECRUITING · started Jul 25, 2024ClinicalTrials.gov NCT06154278 · fetched Nov 12, 2026
Long-Term Follow-up Study for Subjects With CHB Previously Treated With Imdusiran (AB729)RECRUITING · started Jul 11, 2024ClinicalTrials.gov NCT06277037 · fetched Nov 12, 2026
Open-Label Study of AB-729, Nucleos(t)Ide Analogue and Pegylated Interferon Alfa-2a in Subjects With Chronic Hepatitis B InfectionPHASE2 · COMPLETED · started Oct 29, 2021ClinicalTrials.gov NCT04980482 · fetched Nov 12, 2026
Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Intravenous TKM-080301 in Subjects With Advanced Hepatocellular CarcinomaPHASE1_PHASE2 · COMPLETED · started Jun 1, 2014ClinicalTrials.gov NCT02191878 · fetched Nov 12, 2026
A Dose Finding Study of TKM-080301 Infusion in Neuroendocrine Tumors (NET) and Adrenocortical Carcinoma (ACC) PatientsPHASE1_PHASE2 · COMPLETED · started Dec 1, 2010ClinicalTrials.gov NCT01262235 · fetched Nov 12, 2026